139 related articles for article (PubMed ID: 15044223)
21. Evaluation of the hepatotoxic effect of antituberculous drugs in tuberculosis patients abusing alcohol.
Grymiński J; Lyczewska J; Styszewska H; Walczak J
Pol Med J; 1970; 9(3):635-44. PubMed ID: 5452841
[No Abstract] [Full Text] [Related]
22. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
[TBL] [Abstract][Full Text] [Related]
23. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
[No Abstract] [Full Text] [Related]
24. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
Jasmer RM; Daley CL
Am J Respir Crit Care Med; 2003 Mar; 167(6):809-10. PubMed ID: 12623855
[No Abstract] [Full Text] [Related]
25. Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
Garca-Doval I
J Am Acad Dermatol; 2004 May; 50(5):801; author reply 801-2. PubMed ID: 15097974
[No Abstract] [Full Text] [Related]
26. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
27. Hepatoxic reaction to antituberculous drugs: Adjustments to therapeutic regimen.
O'Brien RJ
JAMA; 1991 Jun; 265(24):3323. PubMed ID: 2046117
[No Abstract] [Full Text] [Related]
28. Recurrent dysosmia induced by pyrazinamide.
El Aïdli S; Kastalli S; Zaïem A; Lakhoua G; Rejeibi I; Loueslati MH; Daghfous R; Belkahia C
Fundam Clin Pharmacol; 2009 Oct; 23(5):539-41. PubMed ID: 19674115
[TBL] [Abstract][Full Text] [Related]
29. Interaction between carbamazepine and antituberculosis agents.
Fleenor ME; Harden JW; Curtis G
Chest; 1991 Jun; 99(6):1554. PubMed ID: 2036861
[No Abstract] [Full Text] [Related]
30. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
[TBL] [Abstract][Full Text] [Related]
31. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
Cook PP
Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
[No Abstract] [Full Text] [Related]
32. Gynaecomastia during antituberculosis chemotherapy with isoniazid.
Dixit R; Sharma S; Nawal CL
J Assoc Physicians India; 2008 May; 56():390-1. PubMed ID: 18700651
[No Abstract] [Full Text] [Related]
33. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
Kunimoto D; Warman A; Beckon A; Doering D; Melenka L
Clin Infect Dis; 2003 Jun; 36(12):e158-61. PubMed ID: 12802781
[TBL] [Abstract][Full Text] [Related]
34. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacology, toxicology and clinical use of pyrazinamide (author's transl)].
Zierski M
Prax Klin Pneumol; 1981 Dec; 35(12):1075-1105. PubMed ID: 6808484
[No Abstract] [Full Text] [Related]
36. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
37. Side effects of antituberculosis therapy.
Resi D; Gagliotti C; Moro ML
Am J Respir Crit Care Med; 2004 Feb; 169(4):542; author reply 542. PubMed ID: 14766664
[No Abstract] [Full Text] [Related]
38. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter?
Singh J; Garg PK; Thakur VS; Tandon RK
Indian J Physiol Pharmacol; 1995 Jan; 39(1):43-6. PubMed ID: 7705868
[TBL] [Abstract][Full Text] [Related]
39. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
40. Acute toxic myopathy due to pyrazinamide in a patient with renal transplantation and cyclosporine therapy.
Fernández-Solà J; Campistol JM; Miró O; Garcés N; Soy D; Grau JM
Nephrol Dial Transplant; 1996 Sep; 11(9):1850-2. PubMed ID: 8918638
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
